RFLNYSEPharmaceutical PreparationsFiscal year ends July 31
Rafael Holdings, Inc.
Financials through Q3 FY2026, quarter ended Apr 30, 2026Last filing: 10-Q on Jun 11, 2026
$1.29−0.10 (-7.19%)
Close on Oct 19, 2026
- Market cap
- $66.09M
- P/E (TTM)
- –
- Dividend yield
- –
Rafael Holdings, Inc. revenue by segment
By business segment
| Operating income | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q4 23 | Q3 23 | Q2 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Real Estate [Member] | $17.00K | $28.00K | $12.00K | -$37.00K | $31.00K | $15.00K | -$59.00K | – | – | – | – | – | -45.2% |
| Infusion Technology [Member] | -$8.00K | -$10.00K | -$29.00K | -$28.00K | -$60.00K | -$3.40M | -$263.00K | – | – | – | – | – | -86.7% |
| Healthcare [Member] | -$6.88M | -$6.67M | -$10.12M | -$12.70M | -$5.88M | -$3.26M | -$3.52M | – | – | – | – | – | +16.9% |
By product or service
| Revenue | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q4 23 | Q3 23 | Q2 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product Revenue [Member] | $89.00K | $125.00K | $154.00K | – | $243.00K | – | – | – | – | – | – | – | 49.7% | -63.4% |
| Rental Third Party | $60.00K | $57.00K | – | – | $49.00K | $48.00K | – | – | – | – | – | – | 33.5% | +22.4% |
| Rental Related Party [Member] | $30.00K | $29.00K | – | – | $28.00K | $29.00K | – | – | – | – | – | – | 16.8% | +7.1% |
| Real Estate [Member] | – | – | – | – | – | – | – | – | – | $68.00K | $71.00K | $70.00K | – | – |
| Infusion Technology [Member] | – | – | – | – | $42.00K | $0 | $51.00K | – | – | – | – | – | – | – |
| Infusion Technology Revenue [Member] | – | – | – | – | $42.00K | – | – | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Rafael's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.